The FDA’s advisory committee process just produced the most contradictory week of the year, and it landed exactly where we said the uneven reset would take us—into territory that nobody can predict.
Replimune won a positive advisory committee vote for RP1 in melanoma, despite FDA scientists calling the data package not interpretable just days earlier. That is a genuine surprise. The same week, Capricor got a no on similar footing—negative briefing documents, a skeptical review team, a drug that had already been rejected once. Two previously rejected therapies. Two hostile pre hearing reviews. Opposite outcomes. The FDA’s adcomm process has never looked more like a coin flip when the agency itself is divided.
We described the regulatory reset all year as uneven and improvisational. This week is the sharpest illustration. There is no consistent philosophy you can plan around. One panel looks past the reviewers’ doubts and votes yes. Another sides with them and votes no. The companies absorb the whiplash.
Meanwhile, the AstraZeneca and BMS mega merger talk is dead, and investors cheered its end. Novo fell 6% on a Wegovy pill stumble even though it beat on earnings, and its CEO admitted to setbacks. Amgen grew 10%. Gilead raised guidance. And Moderna launched an early Ebola mRNA vaccine trial.
Replimune Got a Yes After the Worst Possible Setup
What Happened: Replimune won a positive advisory committee vote for its melanoma therapy RP1 despite persistent concerns from FDA scientists, positioning it to recover from two earlier complete response letters, according to BioPharma Dive.
Why This Outcome Surprised Everyone
We covered the setup heading into this hearing. FDA reviewers published briefing documents calling Replimune’s data “not interpretable.” That is about as harsh as agency staff get before a panel meeting. The briefing documents frame how the advisory committee members prepare. Walking into a hearing where the FDA’s own scientists have questioned whether your data can be meaningfully evaluated is, in most cases, walking into a rejection.
The panel voted yes anyway.
That outcome is significant for Replimune and for the industry. For Replimune, a company that received two prior CRLs for RP1, the positive vote is a genuine reprieve. The drug now has a path forward that looked implausible a week ago. RP1 is an oncolytic immunotherapy designed to selectively destroy tumor cells while stimulating the immune system, used in combination with nivolumab in advanced melanoma. If the FDA follows the committee’s recommendation—and the agency is not bound by advisory votes but typically follows them—Replimune could finally achieve the approval it has pursued through three submission cycles. The August FDA response is the next milestone.
For the broader industry, the outcome reinforces the message we have carried all year: the FDA under acting leadership is producing results that are genuinely hard to predict. The briefing documents are not destiny. A panel can look past the reviewers’ concerns, weigh the unmet need and the totality of the evidence differently, and vote yes despite a hostile setup. That injects real variance into outcomes the market often treats as more certain than they are.
The Capricor Contrast Could Not Be Sharper
The same week, Capricor got a negative vote for deramiocel in Duchenne muscular dystrophy cardiomyopathy. The parallels were nearly perfect: a previously rejected drug, skeptical briefing documents, a surprise advisory committee, and a company that did not expect the process to unfold as it did. But where the Replimune panel looked past the doubts, the Capricor panel sided with them.
Capricor’s CEO has said she would not rule out legal action against the FDA, an extraordinary escalation we covered earlier this week. The August 22 PDUFA date still stands, and the FDA can overrule its advisory committees, but a negative panel vote after negative briefing documents makes that path genuinely steep.
Two drugs, two hostile reviews, opposite outcomes. If you are trying to build a model for FDA risk, this week tells you the honest answer: when the agency is internally divided and the science is contested, the adcomm outcome is close to unpredictable. That is the regulatory environment until permanent leadership arrives with a settled philosophy.
Our Pro brief explains what the Replimune/Capricor split reveals about how to model FDA risk now, and why briefing documents predict less than their tone suggests when the agency itself is divided. [Details below.]
The AstraZeneca and BMS Mega Merger Is Dead, and the Market Cheered
What Happened: AstraZeneca and BMS told Reuters they have no ongoing discussions about a potential deal, effectively ending the mega merger speculation that surfaced this week. Notably, AstraZeneca lost tens of billions in market value after the initial reports.
The Market’s Verdict Is the Real Story
We called this deal unlikely on Tuesday and again on Wednesday, framing the talks as a barometer of consolidation pressure rather than a probable transaction. That is how it resolved. But the interesting part is not that the talks ended. It is how shareholders responded when they were alive.
AstraZeneca’s stock fell sharply on the reports of a potential combination—not rose, fell. Investors punished the company for even exploring a deal this large. That is a powerful signal about market appetite for mega mergers. A roughly $400 billion combination carries enormous execution risk: years of integration distraction, antitrust uncertainty across multiple jurisdictions, pipeline disruption, and the well documented tendency of giant pharmaceutical mergers to destroy value rather than create it.
AstraZeneca has been executing well as a focused company—five China deals since the start of 2025, a push toward $80 billion in revenue, Enhertu expanding, Truqap approved, the GSK/Nuvalent dynamic creating competitive opportunity. Its shareholders evidently preferred that focused execution to the gamble of absorbing BMS and its patent cliff challenges. The market said clearly: we like this company as it is, and we do not want it distracted by a transformational deal of dubious value.
What the Death Means for M&A More Broadly
The mega merger dying does not mean consolidation slows down. It means the ceiling on deal size just became more visible. Mid cap consolidation like Supernus and Indivior gets rewarded because the logic is clean and the integration is manageable. The giants continue to do bolt on acquisitions—Lilly’s fifteen deals, AbbVie’s Apogee, GSK’s Nuvalent. But true mega mergers at the very top face a skeptical market that remembers how many have failed. The pressure to get bigger is real. The market just set a limit on how big, and that limit will shape which deals actually happen going forward.
Novo Stumbled Again, and the CEO Said It Out Loud
What Happened: Novo Nordisk fell 6% on a stumble with its Wegovy pill even though it beat on Q2 earnings, and its CEO admitted the company has had a couple of setbacks, according to BioSpace.
The Rough Stretch Now Has a Pattern
We have tracked the contrast between Novo and Lilly all week, setting it Monday and building through the ziltivekimab cardiovascular failure, the CagriSema litigation, the advertising fight, and now the Wegovy pill stumble. Each day has added another data point, and each one has gone the wrong direction for Novo.
The CEO admitting to setbacks is notable because pharmaceutical executives almost never concede publicly that things are going poorly. The language is carefully chosen—”a couple of setbacks” rather than anything stronger—but by the standards of corporate communication from a company of Novo’s stature, it is an unusual concession that reflects real internal pressure.
The 6% share drop on a day when Novo beat its earnings estimates tells you the market is no longer looking at the current quarter. It is looking at the trajectory. And the trajectory for Novo in 2026 has been: CagriSema Phase 3 disappointing on the headline weight loss number. The shareholder lawsuit alleging undisclosed protocol changes. The ziltivekimab cardiovascular failure. The advertising lawsuit against Lilly and escalation to an injunction request. And now the Wegovy pill stumbling at a moment when the oral obesity market is the next critical battleground.
Novo remains a fundamentally strong company with a deep franchise, real science, and enormous obesity revenue. This is a rough patch, not a collapse. But rough patches become trajectories if they are not arrested, and Novo has strung together enough setbacks that the market is treating each new one as confirmation rather than noise. The company needs to change the story with data, not messaging. We will pay off the full obesity thread tomorrow.
Amgen and Gilead Closed Earnings Season Strong
What Happened: Amgen grew revenue 10%, powered by Repatha, Evenity, and newer medicines outweighing biosimilar pressured products. Gilead raised the lower end of its 2026 guidance.
The Q2 Picture Is Now Clear
The earnings season is closing as it ran: broadly strong, with the weak spots concentrated in specific franchises rather than across the board. J&J opened with an oncology miss. Novartis came in steady. GSK topped expectations alongside its $2.5 billion restructuring. BMS raised its outlook despite the Cobenfy delay. Regeneron and Takeda beat. And now Amgen at 10% growth and Gilead raising guidance cap the season.
Amgen at 10% is particularly notable given the company’s complicated year. The Tavneos regulatory crisis—pivotal study retracted, FDA voluntary removal request, CHMP revocation recommendation, ongoing defense—has consumed management attention. But the commercial business kept executing, with Repatha benefiting from the broadening cholesterol treatment market now that Merck’s oral PCSK9 inhibitor Lipfendra is expanding the category, and Evenity continuing to grow in osteoporosis.
Gilead raising guidance continues the theme of the HIV and oncology franchises performing well. The once weekly oral HIV pill data with Merck, the Trodelvy ADC franchise, and the virology portfolio all contribute.
The aggregate message from Q2: the sector is genuinely healthier than it has been in years, the recovery is real, and the numbers backed the mood. Novo is the notable exception—a strong company having a genuinely hard year while the rest of the industry fires on most cylinders.
Moderna Started an Ebola mRNA Vaccine Trial
What Happened: Moderna launched an early clinical trial of an mRNA vaccine targeting the Bundibugyo Ebola strain, a concrete step against the outbreak we have tracked since the WHO declared a Public Health Emergency of International Concern in May.
Why This Matters: The Bundibugyo outbreak in the DRC crossed 1,003 confirmed cases in late June with no approved vaccines or therapeutics for this specific strain. Every existing Ebola countermeasure was developed for the Zaire strain. Moderna’s mRNA platform is the most plausible path to a Bundibugyo specific vaccine because of its speed advantage—designing and producing a new vaccine construct in weeks rather than months.
An early trial will not help the current outbreak. The gap between trial start and authorized vaccine is months at minimum. But it matters for pandemic preparedness and for Moderna’s platform thesis. If the mRNA flu vaccine decision we expect shortly validates the platform for routine commercial use, an Ebola mRNA vaccine would demonstrate that the same manufacturing infrastructure can pivot rapidly to emerging threats. That versatility—seasonal flu in normal years, outbreak response when a new pathogen demands it—is the argument for why the mRNA platform matters beyond any single product.
Quick Hits
Pathos AI signed a $2.09 billion licensing deal with China’s Jiangsu Alphamab for a Trop2 and HER3 bispecific ADC. An AI plus China plus ADC story in a single transaction—three of the year’s dominant themes converging in one deal. The political scrutiny we tracked through the congressional probe and the Biotech Investment National Security Act has not stopped China licensing. The deal flow continues, as we have documented consistently.
Lilly and Resilience are investing $750 million to create 400 jobs making GLP 1 injectables. This is the Section 232 tariff structure working exactly as designed—incentivizing domestic manufacturing investment from the companies with the most to gain from onshoring. Lilly’s Zepbound franchise needs manufacturing capacity, the tariffs make imported production more expensive, and the $750 million investment builds the domestic capacity to match the demand.
The IPO window is wide open. Apnimed raised $192 million, above its targets, and five more drugmakers including Braveheart Bio and Latigo set terms and could price this week. The pipeline of debuts is pushing 2026 toward its strongest IPO year since 2021, confirming the capital markets health we have tracked throughout the year.
Strategic Themes
1. The FDA’s Adcomm Process Has Never Looked More Unpredictable
Replimune yes. Capricor no. Both after hostile briefing documents. Both for previously rejected drugs. Both in the same week. The lesson is not that briefing documents do not matter. They do. But when the agency itself is divided and the science is contested, the advisory committee outcome is close to unpredictable. Companies should build adcomm variance into every rare disease and borderline filing timeline, and investors should recognize that the market tends to overprice negative briefing documents in cases where the panel has room to disagree.
2. The Mega Merger Is Dead, and the Market Set a Size Limit on Consolidation
AstraZeneca’s shareholders punished the stock on the prospect of a $400 billion combination and cheered its end. The signal is clear: investors prefer focused execution to transformational mega deals. Mid cap consolidation and bolt on acquisitions will continue vigorously. But the very largest combinations face a market that has seen too many fail and does not want the disruption. The consolidation wave runs on, but it has a ceiling, and this week revealed where it sits.
3. Novo Is Having a Genuinely Hard Year, and the CEO’s Admission Confirms It
A 6% drop on a day you beat earnings. A CEO conceding setbacks publicly. A Wegovy pill stumble on the oral battleground that matters most. Each individual event is manageable. The accumulation is the problem. Novo needs data to change the story—CagriSema delivering unambiguously, the oral franchise executing cleanly, a pipeline win that reestablishes the company at the frontier. Until then, each new stumble lands harder because the market is treating them as confirmation of a trajectory rather than isolated incidents.
4. Q2 Earnings Confirmed the Recovery, and the Numbers Held Up
Amgen 10%. Gilead raised guidance. GSK topped expectations. Novartis beat. BMS raised its outlook. J&J’s oncology miss was the outlier, not the pattern. The sector is broadly healthy, the recovery is real, and the financial foundation that supports the record M&A pace, the reopened IPO window, and the friendlier regulatory posture is confirmed by the companies’ own results.
Frequently Asked Questions
Did Replimune win its advisory committee?
Yes. The panel voted positively for RP1 in melanoma despite FDA reviewers calling the data “not interpretable.” It is a genuine surprise and positions Replimune to recover from two prior CRLs. The August FDA response is the next milestone.
What happened with the AstraZeneca/BMS merger?
Both companies told Reuters they have no ongoing discussions. AstraZeneca lost tens of billions in market value on the initial reports and recovered when the talks were denied. The market clearly preferred the focused company to the mega combination.
Why did Novo fall 6%?
A stumble with its Wegovy pill, even though the company beat Q2 earnings estimates. The CEO admitted to a couple of setbacks. The market is now treating each Novo disappointment as confirmation of a negative trajectory rather than an isolated event.
How did Amgen and Gilead do?
Amgen grew revenue 10%, powered by Repatha and Evenity. Gilead raised the lower end of its 2026 guidance. Both closed out a broadly strong Q2 earnings season.
What is Moderna doing on Ebola?
Launched an early clinical trial of an mRNA vaccine targeting the Bundibugyo Ebola strain. It will not help the current outbreak but matters for future preparedness. The mRNA platform’s speed advantage makes it the most plausible path to a strain specific Ebola vaccine.
What is the Pathos AI deal?
A $2.09 billion licensing deal with China’s Jiangsu Alphamab for a Trop2 and HER3 bispecific ADC. An AI, China, and ADC story in one transaction. The China deal flow continues despite the congressional probe.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Replimune Won, Capricor Lost, Same Week. We explain what the split reveals about how to model FDA advisory committee risk now, why briefing documents predict less than their tone suggests when the agency is divided, and how to price the variance in every pending rare disease decision.
The Mega Merger Is Dead, and the Market Set a Ceiling. We analyze what AstraZeneca’s shareholder punishment says about appetite for the very largest deals, assess where the size limit sits, and evaluate how this shapes the M&A landscape for the second half.
Novo Needs a Win, and These Are the Two That Matter. We lay out what CagriSema and the oral obesity franchise need to deliver to reset Novo’s narrative, assess whether the company can stabilize before the perception of Lilly dominance hardens into consensus, and evaluate the strategic options if the data do not cooperate.
Plus: Amgen and Gilead earnings wrap, Pathos AI $2.09B China ADC deal, Lilly $750M manufacturing investment, IPO market update, Moderna Ebola trial, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
